Cromatina/Epigenetica
Gli inibitori della cromatina/epigenetica sono composti che modulano la struttura e la funzione della cromatina o interferiscono con le modificazioni epigenetiche, come la metilazione del DNA e la modifica degli istoni. Questi inibitori sono strumenti essenziali per studiare la regolazione dell'espressione genica e il ruolo dell'epigenetica in malattie come il cancro, i disturbi neurologici e le anomalie dello sviluppo. Mirando ai processi epigenetici, questi inibitori possono alterare i modelli di espressione genica e offrire nuove opportunità terapeutiche. Presso CymitQuimica, offriamo un'ampia selezione di inibitori della cromatina/epigenetica di alta qualità per supportare le tue ricerche in biologia molecolare, genetica ed epigenetica.
Sottocategorie di "Cromatina/Epigenetica"
Trovati 2540 prodotti di "Cromatina/Epigenetica"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC SMARCA2/4-degrader-27
CAS:PROTAC SMARCA2/4-degrader-27 (PROTAC 2) serves as a targeted degrader, utilizing PROTAC technology to degrade both SMARCA2 and SMARCA4.Formula:C49H58FN9O6SColore e forma:SolidPeso molecolare:920.11Bryostatin 2
CAS:Protein kinase C (PKC) activatorFormula:C45H66O16Purezza:98%Colore e forma:SolidPeso molecolare:863BETd-246
CAS:BETd-246 is an inhibitor of second-generation and PROTAC-based BET bromodomain (BRD), show antitumor activity.Formula:C48H55N11O10Purezza:98%Colore e forma:SolidPeso molecolare:946.02Ref: TM-T14549
5mg485,00€10mg710,00€25mg1.449,00€50mg2.197,00€100mgPrezzo su richiesta200mgPrezzo su richiestaSIRT1/2/3-IN-1
CAS:Potent SIRT1/2/3-IN-1 inhibits SIRT1/2/3 with IC50: 0.54, 0.25, 0.72 μM; used in cancer research.Formula:C46H63N9O8S2Colore e forma:SolidPeso molecolare:934.18MT1
CAS:MT1, a bivalent chemical probe targeting BET bromodomains, demonstrates an IC50 value of 0.789 nM for BRD4(1).Formula:C54H66Cl2N10O9S2Colore e forma:SolidPeso molecolare:1134.2AURKA against 1
Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.
Formula:C28H32FN9O2Colore e forma:SolidPeso molecolare:545.61Pep2m, myristoylated
CAS:Myristoylated pep2m peptide; inhibits GluA2-NSF interaction, reducing AMPA receptor function and surface expression.Formula:C63H118N18O14SPurezza:98%Colore e forma:SolidPeso molecolare:1383.8MS2133
MS2133 is a DOT1L PROTAC degrader. It facilitates the ubiquitination and degradation of DOT1L in THP-1 and MV4-11 cells, with DC50 values of 56 nM and 25 nM, respectively, and reduces H3K79 methylation. MS2133 also inhibits the growth of MLL-r leukemia cells, demonstrating anticancer activity.Formula:C58H66ClF3N14O11S2Colore e forma:SolidPeso molecolare:1290.41175NF-κB/HIF-1α-IN-1
NF-κB/HIF-1α-IN-1 (compound 9c) effectively inhibits the NF-κB activation pathway and demonstrates selective antifibrotic activity. This compound exhibits no significant cytotoxicity in NCI tumor cell lines. In rat models, NF-κB/HIF-1α-IN-1 successfully ameliorates liver fibrosis, suppresses the expression levels of NF-κB and HIF-1α, and induces Nrf2.Formula:C24H27N7O4Colore e forma:SolidPeso molecolare:477.21245PROTAC SMARCA2/4-degrader-31
CAS:PROTAC SMARCA2/4-degrader-31 (Compound I-280) serves as a degrader for the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It effectively degrades SMARCA2 in A549 cells and SMARCA4 in MV411 cells, both with a degradation concentration (DC50) of less than 100 nM.Formula:C44H51N11O4Colore e forma:SolidPeso molecolare:797.95MOCPAC
CAS:MOCPAC is an HDAC1 specific substrate [1] .Formula:C27H31N3O6Colore e forma:SolidPeso molecolare:493.55Neuropeptide DF2
CAS:Neuropeptide DF2 is an FMRFamide-related neuropeptide from crayfish.Formula:C44H67N15O10Purezza:98%Colore e forma:SolidPeso molecolare:966.1ZINC000014708529
ZINC000014708529 is a potent SIRT7 inhibitor exhibiting high affinity for SIRT7 and is utilized in cancer research [1].Colore e forma:Odour SolidOARV-771
CAS:OARV-771: VHL-based PROTAC targeting BET; DC50: Brd4-6nM, Brd2-1nM, Brd3-4nM; enhanced cell permeability.Formula:C49H59ClN8O8S2Colore e forma:SolidPeso molecolare:987.62OKI-006
CAS:OKI-006 is an oral HDAC inhibitor with potential for cancer research, derived from largazole.Formula:C21H30N4O5S2Colore e forma:SolidPeso molecolare:482.62JAK-IN-15
CAS:JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).Formula:C22H23FN4O3SColore e forma:SolidPeso molecolare:442.51mTOR/HDAC-IN-1
CAS:mTOR/HDAC-IN-1, a dual inhibitor for mTOR & HDAC1 with IC50s 0.49 & 0.91 nM, potential anti-cancer agent.Formula:C23H23N11O3Colore e forma:SolidPeso molecolare:501.5PROTAC HDAC6 degrader 4
PROTAC HDAC6 degrader4 (Compound 17c) is a PROTAC that targets and degrades HDAC6, with a DC50 of 14 nM. It exhibits inhibitory activity against HDAC1, HDAC2, HDAC3, and HDAC6, with IC50 values of 2.2, 2.37, 0.61, and 0.295 μM, respectively. [Pink: ligand for target protein HDAC6 ligand-3; Black: linker; Blue: ligand for cereblon E3 ligase]Formula:C39H42FN9O7Colore e forma:SolidPeso molecolare:767.81DNMT1/HDAC-IN-1
DNMT1/HDAC-IN-1 (compound (R)-23a), a potent dual inhibitor targeting both DNMT1 and HDAC, exhibits impressive inhibitory effects specifically on HDAC1 (HDAC1:IC50=0.05 μM), a major HDAC isoform that interacts with DNMT1 across multiple protein complexes involved in the transcriptional silencing of TSGs. This compound has been shown to remodel the tumor immune microenvironment and induce tumor regression, effectively reversing cancer-specific epigenetic abnormalities.Colore e forma:Odour Solid
